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Introduction: Recurrent thrombotic events are a hallmark of Antiphospholipid Syndrome
(APS). However, biomarkers to identify if a patient with antiphospholipid antibodies (aPL)
is at higher risk to develop an arterial or a venous event are lacking. Recently, the
pathogenic role of anti-high-density lipoproteins antibodies (anti-HDL) in the occurrence
of cardiovascular disease (CVD) in autoimmunity has emerged. The aim of the present
study was to evaluate the presence of IgG anti-HDL antibodies in a cohort of thrombotic
APS patients and to investigate their association with clinical outcomes.
Methods: Serum levels of IgG anti-HDL antibodies, total IgG, and complete aPL profile
were assessed in 60 APS patients and 80 healthy donors (HDs) by immunoassays.
Results: Higher levels of IgG anti-HDL were found in APS patients compared to HDs
(p < 0.001), even after correcting for total IgG levels (p < 0.001). No associations
with treatments or traditional cardiovascular risk factors, except for smoking habit (p
< 0.0001), were found. Patients who experienced at least one arterial event (n= 30) had
significantly higher levels of anti-HDL antibodies when compared to patients with venous
thrombosis (n= 30, p= 0.046), this difference being stronger when adjusting for total IgG
(p = 0.007). Additionally, patients tested positive for antiphosphatidylserine/prothrombin
(IgG/IgM) antibodies had significantly higher levels of anti-HDL antibodies (p = 0.045).
Conclusions: Increased levels of IgG anti-HDL antibodies can be found in APS, mainly
in patients with arterial thrombosis, independently of aPL antibodies and traditional risk
factors. These findings point to a role of anti-HDL antibodies in APS and support their
use as a potential biomarker for arterial thrombotic events.
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INTRODUCTION
Antiphospholipid Syndrome (APS) is the most common
acquired thrombophilia. At the clinical level, APS is defined
by the occurrence of thrombotic events, with the peculiar
trait of potentially involving both arteries and veins and/or
pregnancy morbidity, in individuals found to be persistently
positive for antiphospholipid antibodies (aPL), including:
lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-
β2glycoprotein I (anti-β2GPI) antibodies (1). Additionally,
premature cardiovascular disease (CVD) and atherosclerotic
development have been proven to be more prevalent in APS
compared to the general population (2, 3).The mechanisms
underlying thrombosis and CVD in APS patients are not
completely understood, but recent evidences have brought to
light the existence of a complex interplay between conventional
cardiovascular risk factors and disease-specific features, such as
the presence of autoantibodies (4).
Interestingly, several studies have reported that aPL
might be able to cross-react with lipoproteins and their
components, contributing to endothelial dysfunction, enhancing
atherosclerosis, and ultimately leading to CVD progression (5, 6).
However, the clinical relevance of such findings is unknown.
In addition, recent studies have discovered the existence of a
heterogeneous group of autoantibodies specifically directed
against lipoproteins and their components, namely IgG anti-
high-density lipoproteins antibodies (anti-HDL), which have
been demonstrated to impair the anti-inflammatory and anti-
oxidative roles exerted by HDL-cholesterol (7). Higher anti-HDL
levels have been described in a broad range of autoimmune
diseases (8–10). However, whether anti-HDL antibodies may
be associated with clinical features in APS remains unclear.
Critically, while it is known that the presence of aPL confers a
high risk for thrombosis (11), biomarkers to if a patient is at
higher risk to develop an arterial or a venous event are lacking.
The aim of the present study was to evaluate the presence of
IgG anti-HDL antibodies in a cohort of thrombotic APS patients
and to investigate if these antibodies can discriminate between
arterial and venous thrombosis.
METHODS
Ethics Statement
The study protocol, involving human samples, was performed in
compliance with the Declaration of Helsinki and reviewed and
approved by the Institutional Review Boards (IRBs) from the
University of Turin and the University of Oviedo. All participants
gave written informed consent prior enrolment.
Patients
This cross-sectional study included 60 APS patients attending
the Giovanni Bosco Hospital, Turin, Italy. Inclusion criteria
comprehended: patients with persistent aPL positivity
and that fulfilled the Sydney criteria for thrombotic APS
(venous and/or arterial) (1). A group of 80 age- and sex-
matched healthy individuals from the same population was
recruited as healthy donors (HDs). Medical records from
APS were retrospectively revised in order to register clinical
characteristics, including previous episodes of venous and/or
arterial thrombosis. Blood samples were collected after the first
thrombotic event.
Antiphosholipid Antibodies Testing
The aPL profile included LA, aCL, and anti-ß2GPI, and anti-
phosphatidylserine/prothrombin (aPS/PT) antibodies. The aCL,
anti-ß2GPI, aPS/PT (IgG and IgM) were semi-quantitatively
assayed using a commercial ELISA kit by Inova Diagnostics, Inc
(San Diego, CA, United States).
Plasma samples were tested for the presence of LA according
to the recommended criteria from the International Society
on Thrombosis and Haemostasis Subcommittee on Lupus
Anticoagulant/Phospholipid-Dependent Antibodies (12, 13).
IgG Anti-HDL Antibodies
IgG antibodies against HDL were measured in all serum samples
by ELISA as previously described (9). ELISA plates (Maxisorp,
Nunc) were coated overnight (4◦C) with 20µg/ml human HDL-
cholesterol (Sigma) in 70% ethanol (test half) or ethanol alone
(control half). Then, plates were blocked with PBS + 1% BSA
(Sigma) for 1 h at room temperature andwashedwith PBS. Serum
samples (1:50-diluted in PBS + 0.1% BSA), and standard curves
from pooled sera (diluted 1:16 to 1:512) were incubated in both
plate halves for 2 h at room temperature. Plates were then washed
twice with TBS and alkaline phosphatase-conjugated anti-human
IgG (1:1,000) (Immunostep) was added for 1 h. Finally, p-
nitrophenylphosphate (Sigma) in diethanolamine buffer (pH 9.8)
was added and absorbance at 405 nm was recorded. Anti-HDL
Arbitrary Units (AU) were calculated for each sample according
to the standard curves. Intra- and inter-assay reproducibility
for our assay was 10 and 13%, respectively. Total IgG was
quantified by conventional ELISA techniques and AU values
obtained from the anti-HDL ELISA were corrected using
total IgG levels (anti-HDL/IgG). The positivity to anti-HDL
antibodies was evaluated using the 90th percentile of the
anti-HDL/IgG in HDs (=12.94) as cut-off (9). This cut-off
provided the following analytical estimates in the present study:
sensitivity = 0.46, specificity = 0.90, and positive predictive
value= 0.91.
Statistical Analysis
Categorical variables are presented as number (%) and
continuous variables are presented as mean (S.D.). Differences
were evaluated by the chi-squared test, Fisher’s exact test
or the unpaired t-tests (Mann–Witney or Kruskal–Wallis),
as appropriate. Spearman rank’s test was used to analyze
correlations. ROC curves were performed to evaluate the
association between anti-HDL positivity and thrombotic
outcomes, and the corresponding area under the curve (AUC)
and its 95% confidence intervals and p-values were computed. A
two-sided P < 0.050 was considered as statistically significant.
All statistical analyses were performed using SPSS version 19.0
(IBM, Armonk, NY, USA).
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RESULTS
IgG Anti-HDL Antibodies in APS Patients
Sixty APS patients were enrolled in this study, 43 (71.6%) patients
being primary APS patients (PAPS) and 17 (28.4%) patients
having a concomitant diagnosis of SLE, according to the recently
approved classification criteria of the European League Against
Rheumatism and the American College of Rheumatology, which
includes at least one positive antinuclear antibody test and the
combination of a number of clinical and immunological criteria
(14). All 60 patients had at least one thrombotic event: 30
(50%) previous arterial events and 37 (61.6%) venous events
(seven patients experienced recurrent events, both venous and
arterial). For the purpose of this study the analysis was performed
taking into account the first thrombotic event, meaning that 30
patients were considered as arterial thrombotic APS patients and
30 patients as venous thrombotic APS patients. No differences
have been found between PAPS and secondary APS patients
(SAPS) in terms of age (p = 0.190), gender (p = 0.21),
cardiovascular risk factors [including arterial hypertension (p
= 0.281), hyperlipidemia (p = 0.670), and smoking habit (p
= 0.290)], C-reactive protein values (p = 0.540) and HDL
cholesterol levels (p = 0.721), and aPL profile (all p > 0.050).
In addition, no differences have been found when looking at
the levels of anti-HDL antibodies between these two groups
(p = 0.570), even when correcting for total IgG levels (p =
0.860). One SAPS patient had undergone B-cell depletion therapy
within 1 year prior to blood sample collection. Full demographics
and clinical characteristics of the study cohort are detailed in
Table 1.
Higher levels of IgG anti-HDL were found in APS patients
compared to HDs [mean 46.1 (SD ±69.8) vs. mean 14.3 (SD
±14.5), respectively; p < 0.001] (Figure 1A). Anti-HDL levels
were found to be increased even after correcting for total
IgG levels [mean 12.6 (SD ±16.3) vs. mean 4.7 (SD ±5.5),
respectively; p < 0.001] (Figure 1B).
The levels of anti-HDL antibodies were not associated with
traditional CV risk factors, including arterial hypertension (p =
0.800), hyperlipidaemia (p = 0.102), diabetes (p = 0.700), and
high body mass index (p = 0.800). Anti-HDL levels were not
correlated to HDL levels in APS (r = 0.090, p = 0.630) nor in
HDs (r = 0.110, p = 0.370). Similar results were retrieved when
APS patients were analyzed separately as PAPS and SAPS (r =
0.120, p= 0.561; and r=−0.050, p= 0.710; respectively). On the
contrary, higher levels of anti-HDL antibodies were observed in
smokers compared with non-smokers [mean 112.42 (SD±202.2)
vs. mean 36.6 (SD ±38.7); p < 0.0001], even after adjusting for
total IgG levels [anti-HDL/IgG: mean 16.2 (SD ±26.2) vs. mean
10.9 (SD ±11.1); p = 0.012]. Finally, levels of total IgG were
found to be similar between APS patients and HDs [mean 382.23
(SD±154.88) vs. mean 333.63 (SD±115.37); p= 0.262] and not
related to clinical parameters, thrombosis status or treatments (all
p > 0.050).
Overall, an increased prevalence of IgG anti-HDL antibodies
can be observed in APS patients. Traditional CV risk factors
were not related to anti-HDL levels, with the exception of
smoking habit.
TABLE 1 | Demographic, clinical, and laboratory characteristics of the APS





Female sex (n, %) 60 (75) 43 (71.6)
Age (mean, S.D.), years 48.6 ± 10.4 50 ± 10.8
Primary APS patients (n, %) 0 (0) 43 (71.6)
Concomitant diagnosis of SLE (n, %) – 17 (28.3)
Disease duration since APS diagnosis
(mean, S.D.), years
– 11.7 ± 7.5
Thrombosis (n, %) 0 (0) 60 (100)
Venous thrombosis (n, %) – 37 (61.6)*
Arterial thrombosis (n, %) – 30 (50)
Pregnancy morbidity (n, %) 0 (0) 1 (1.6)
Arterial hypertension (n, %) 4 (5) 22 (36.6)
Hyperlipidemia (n, %) 0 (0) 19 (31.6)
Smoking (n, %) 9 (11.2) 5 (8.3)
Obesity (BMI > 30) (n, %) 0 (0) 8 (13.3)
LA (n, %) 0 (0) 49 (81.6)
aCL IgG/M (n, %) 0 (0) 38 (63.3)
Anti-β2 GPI IgG/IgM (n, %) 0 (0) 29 (43)
aPS/PT IgG/IgM (n, %) 0 (0) 29 (48.3)
Triple aPL positivity (n, %) – 20 (33.3)
Total cholesterol levels (mean, S.D.), mg/dl 145 ± 32.2 187.4 ± 51
HDL-cholesterol levels (mean, S.D.), mg/dl 72 ± 15.3 64 ± 9.1
Triglycerides levels (mean, S.D.), mg/dl 104 ± 26.2 98.7 ± 28.6
CRP levels (mean, S.D.), mg/dl 0.23 ± 0.2 0.45 ± 0.2
Statins (n, %) 0 (0) 20 (33.3)
Anti-hypertensive drugs (n, %) 3 (5) 19 (31.6)
HCQ (n, %) 0 (0) 15 (25)
Anticoagulant agents (n, %) 0 (0) 33 (55)
Antiaggregant agents (n, %) 0 (0) 36 (60)
B-cell depletion agent (Rituximab) (n, %) 0 (0) 1 (1.2)
*Seven patients experienced recurrent thrombotic events, both venous and arterial.
For the purpose of this study the analysis was performed taking into account the first
thrombotic event, meaning that 30 patients were considered as arterial thrombotic APS
patients and 30 patients as venous thrombotic APS patients. APS, antiphospholipid
syndrome; HDs, healthy donors; SLE, systemic lupus erythematosus; BMI, adult body
mass index; LA, lupus anticoagulant; aCL, anti-cardiolipin antibodies; anti-β2 GP1, anti-
β2glycoprotein I antibodies; aPS/PT, antiphosphatidylserine/prothrombin antibodies; aPL,
anti-phospholipid antibodies; CRP, C-reactive protein; HCQ, hydroxychloroquine.
IgG Anti-HDL Antibodies and Clinical
Features in APS Patients
When separating for individual aPL positivities, patients tested
positive for aPS/PT (IgG/IgM) antibodies had significantly higher
levels of anti-HDL [mean 53.1 (SD ±81.1) vs. mean 20.7 (SD
±17.6); p = 0.045], which did not reach statistical significance
after adjusting for total IgG (p = 0.151). No differences were
observed with the rest of aPL tested. Similarly, no differences
were observed when the different isotypes of aPL antibodies
(IgG/IgM) were entered separately in the analyses (all p> 0.050).
Additionally, no differences were observed between patient
with primary APS and those with a concomitant autoimmune
diagnose. Finally, IgG anti-HDL levels were not associated with
treatments received (all p > 0.050).
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FIGURE 1 | Anti-HDL antibodies in APS patients. Levels of IgG anti-HDL antibodies measured as AU (A) or normalized after total IgG correction (B) in APS patients
(n = 60) and HDs (n = 80). Bars indicate 25th, median and 75th percentiles. Differences were assessed by Mann–Whitney U-tests.
ROC analyses (Supplementary Figure 1) revealed a good
discriminative power of the anti-HDL positivity to the presence
of thrombosis (both arterial and venous) (AUC ROC [95% CI], p:
0.751 [0.633, 0.870], p < 0.001), hence strengthening their role as
potential biomarker.
Finally, when separating patients for the different thrombotic
manifestations of APS (arterial vs. venous), we observed that
patients who experienced at least one arterial event had
significantly higher levels of anti-HDL when compared to
patients with venous thrombosis [mean 53.1 (SD ±94.1) vs.
mean 34.3 (SD ±28.9), respectively; p = 0.046] (Figure 2A).
This difference became stronger when adjusting for total IgG
levels [anti-HDL/IgG: mean 13.1 (SD ±16.7) vs. mean 9.5
(SD ±6.6); p = 0.007] (Figure 2B, right panel). No significant
difference was found in total IgG levels between patients who
experienced an arterial or a venous thrombotic event [mean
378.2 (SD ±148) vs. mean 375.5 (SD ±136.3), respectively; p =
0.950]. Importantly, none of the aPL antibodies differ between
arterial and venous thrombosis, and no differences were observed
for clinical features and treatments received (all p > 0.050).
Furthermore, the distribution of traditional CV risk factors was
similar between both subsets of APS patients (all p > 0.050).
Taken together, our results confirm that anti-HDL antibodies
were associated with clinical outcomes in APS, as aPS/PT
positivity and arterial thrombotic manifestation, independently
of other clinical features, hence suggesting its potential use
as biomarkers.
DISCUSSION
Autoimmune and rheumatic diseases are associated with a
higher prevalence of CV morbidity and mortality, mainly due
to an accelerated atherosclerotic process (15, 16). Far from the
early conception of a natural, evolutive aging-related process,
a compelling body of evidence supports that atherosclerosis
and atherothombosis are dynamic and complex conditions
resulting from an inextricable link of multiple pathogenic factors
that trigger and perpetuate the vascular damage and impair
its reparative mechanisms (17). Immune (systemic) mediators
and autoantibodies emerge as crucial pathogenic players in
this scenario. Therefore, atherosclerosis and atherothrombosis
are now seen as the consequence of the interplay between
traditional risk factors and autoimmune-related mechanisms
(18). As a consequence, the presence of traditional CV risk factors
alone cannot fully explain the increase CV morbidity (18). In
addition, although the presence of chronic inflammation and
the production of disease-specific antibodies, such as aPL, play
a crucial role in the pathogenesis of endothelial dysfunction and
thromboembolic manifestations, the exact mechanisms involved
are largely unknown and recent evidence seem to point to
the involvement of novel mediators. The results presented in
this paper suggest the involvement of a new player, anti-HDL
antibodies, in this scenario. If validated in larger prospective
studies, our findings might also support the potential use anti-
HDL antibodies as biomarkers for the early identification of
patients with arterial thrombosis.
Despite previously being considered as mere bystanders,
lipoproteins are important and active mediators of pathogenic
processes such as inflammation, oxidative stress, and metabolic
traits in autoimmunity. In fact, altered lipoprotein levels
and/or functionality have been reported in several autoimmune
conditions. In recent years, a growing body of evidence has
highlighted the involvement of anti-HDL antibodies as a bridge
between humoral immune-response, lipid dysfunction, oxidative
status, and clinical outcomes in rheumatic disorders (8, 19, 20).
To date, in the specific setting of APS, limited data are available
regarding lipid profile and the association of anti-HDL with
clinical features of the disease had been unexplored. Previous
studies have demonstrated increased levels of anti-HDL in APS
patients when compared to HDs and SLE patients without APS
(6, 7, 21) In addition, increased levels of anti-HDL were found to
be inversely correlated with the levels of paraoxonase-1 (PON1),
accounting for the antioxidant effect of HDL (22). In line with
the data available in the literature so far, our study showed that
APS patients presented significantly increased levels of IgG anti-
HDL when compared to HDs, hence confirming this result in
the larger APS cohort analyzed until date. Interestingly, our
results went further by confirming that this result remained after
correcting for total IgG levels, thus suggesting that higher levels
of anti-HDL antibodies cannot be attributed to a general over-
activation of the immune system in the context of autoimmunity,
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FIGURE 2 | Anti-HDL antibodies and clinical features in APS. Levels of IgG anti-HDL antibodies measured as AU (A) or normalized after total IgG correction (B) in
APS patients with arterial thrombosis (n = 30, gray dots), venous thrombosis (n = 30, open dots) (Table 1) and HDs (n = 80, open triangles). Differences were
assessed by Kruskal–Wallis tests and p-values indicated were derived from Dunn–Bonferroni tests for multiple comparisons.
but to the specific production of these antibodies. Additionally,
the emergence of anti-HDL antibodies in APS was not linked to
the positivity of other aPL antibodies or treatments. Moreover,
anti-HDL were not related to traditional CV risk factors in APS
patients, in line with previous findings in SLE and RA cohorts
by our group and others (9, 21), thus strengthening their role as
independent, complimentary biomarkers.
A remarkable finding from our study was the association
with arterial thrombosis. Even if deep vein thrombosis
represents the most common feature of APS, arterial events
constitute the most dangerous and potentially life-threatening
manifestations of the disease, affecting primarily the central
nervous system and young adults <50 years old (3, 23, 24)
Although some progresses have been made in order to
identify those patients who are at higher risk for developing
arterial events, it still represents an urgent unmet clinical
need (25–27).
When analyzing the association between anti-HDL and
clinical manifestation of APS in our study, we found statistically
significant higher levels of IgG anti-HDL in those patients
who have a history of arterial events. This result suggests that
arterial APS patients might display a prominent impairment of
the anti-atherogenic function of HDL, which represent a key
step in endothelial dysfunction, oxidative stress, atherosclerotic
plaque formation and progression, ultimately leading to
atherothrombotic manifestations. Importantly, no differences
in other clinical and laboratory parameters have been found
between these groups of patients. If our observation were
confirmed in larger prospective studies, IgG anti-HDL might
represent an additional tool to CV risk factors profiling in
the identification and management of “high-risk patients,”
which might guide the therapeutic strategies. In fact, the
recent RAPs and TRAPs trials (28, 29) have reported different
results when it comes to using new agents for venous and
arterial events, hence strengthening the validity of our findings
as biomarkers for the clinical setting. In this context, “high
risk patients” might benefit of combined thrombo-prophylactic
therapy as primary (e.g., anti-platelets and hydroxycholoroquine)
or secondary prophylaxis (anti-platelets/hydroxycholoroquine
associated to VKA) (30); similarly, they might be discouraged
to the use of direct oral anticoagulants (31, 32). However, the
real impact of IgG anti-HDL testing on therapeutic patients’
management is not addressable in this study due to its cross-
sectional design.
As mentioned above, our data showed that higher levels
of anti-HDL were found in smokers. The link between smoke
and autoimmunity has been already described in a wide
range of pathologic conditions (33). Cigarette smoking exerts
several pro-inflammatory effects, increasing oxidative stress,
inducing the release of intracellular antigens, the augmentation
of auto-reactive B-cells activity and an overall production of
autoantibodies, including aPL (34). In this context, smoking
might represent an important environmental trigger for anti-
HDL production, and a potential mechanistic link between
this risk factor and the occurrence of either thrombotic-
embolism or atherosclerosis development, the main clinical
outcomes related to anti-HDL in the literature. However,
further analyses are needed in order to clarify this possible
association from a mechanistic point of view and its clinical
impact in APS.
Finally, our study shed new light into the associations
between anti-HDL and disease-related autoantibodies. On the
one hand, early studies from other groups reported certain
degree of cross-reactivity between aCL and anti-HDL antibodies
(6), although this was not confirmed in other studies (6).
Importantly, previous analyses on these antibodies in APS
were performed in low sample size populations. Our findings
revealed no association between anti-HDL and aCL antibodies,
challenging the previous notion. This is in line with previous
studies from our group when analyzing other disease-related
autoantibodies positivity (8–10). Recent advances have brought
to light the existence of a heterogeneous group of pathogenic
autoantibodies in APS. Among them, aPS/PT antibodies have
been proven to have a clinical independent relevance in this
setting (35), confirmed in international studies by our group
and others (36, 37). In our analysis, despite anti-HDL levels
not showing any association other aPL antibodies, patients
tested positive for aPS/PT antibodies exhibited higher levels
of anti-HDL. As the clinical role of aPS/PT is a rising topic,
particularly when other aPL tests are negative, this association
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could be of special interest and could make a case for
anti-HDL as new potential biomarkers in this specific subset
of patients.
This study has potential limitations, including mainly the
cross-sectional retrospective design and the limited sample size.
Indeed, prospective larger studies are needed to confirm these
findings. However, our study documented, in line with the
data available in the literature about the presence of IgG anti-
HDL antibodies in APS and expanded the current knowledge
about the emerging role of these autoantibodies in autoimmune-
mediated diseases and CVD. Moreover, whether anti-HDL
antibodies could be also associated with other surrogate markers
of CVD (such as subclinical atherosclerosis), in addition to their
association with thrombosis, remains to be elucidated. Similarly,
patients exhibiting both arterial and venous events were not
analyzed separately due to sample size concerns. Further studies
may elucidate if these patients show a different/intermediate
profile of anti-HDL antibodies. On the other hand, it may be
interested to analyze whether anti-HDL antibodies may be linked
to aPL-pregnancy related complications. However, due to sample
size concerns and potential clinical differences (38), this was
not explored in our study. Additionally, although differences in
hyperlipidemia were observed between patients and controls, the
lack of association between lipid profiles and anti-HDL levels,
and the relatively small differences in lipid levels between these
two groups lead us to think that this do not represent a major
limitation for our findings. This point is also supported by the
existing literature findings (8, 39–44). In summary, to the best
of our knowledge, this is the first study informing an association
between anti-HDL antibodies and thrombotic outcomes in APS
patients. Our study warrants future pathogenic studies are
needed to confirm such observations. Moreover, our findings
support that anti-HDL might represent a promising tool for risk
management and assessment and a reliable biomarker for the
early identification of arterial thrombotic events. Despite some
preliminary evidence (6, 45), exploring the role of autoantibodies
against lipoprotein components is still intriguing in the APS
setting, as their increased thrombotic and atherothrombotic
profile might support the need of targeted specific approaches.
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